GeneDx
Runs exome and genome testing for pediatric and rare-disease diagnosis.
Something off on this page? Send us feedback.
Profile
Provides ExomeDx and GenomeDx testing, interpretation, and related data services for pediatric and rare-disease care. Revenue is concentrated in U.S. diagnostics, with adoption tied to clinician ordering, institutional programs, and third-party reimbursement.
ExomeDx, GenomeDx, and rapid genome offerings anchor a diagnostics business focused on pediatric and rare-disease patients. GeneDx Infinity supports test interpretation, while Fabric Genomics adds software and services for genomic data analysis and biopharma customers.
Sales are concentrated in the United States through clinician referrals, institutional customers, and a field team that works with pediatric specialists, neonatal intensive care units, and late-stage prenatal programs. International revenue is small, though Fabric Genomics adds a broader software channel.
Execution depends on turning complex genome data into clinical answers and expanding use of exome and genome testing. The business also depends on third-party coverage, institutional contracts, and reimbursement rates for tests performed.
Company facts
Key statistics
Year to date −34.7% · Average volume (30d) 724.8K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 4, 2026 | Canaccord Genuity | Reiterate | Buy | $75 | $90 |
| Jun 29, 2026 | Guggenheim | Reiterate | Buy | $70 | $74 |
| Jun 23, 2026 | Piper Sandler | Reiterate | Overweight | $130 | $63 |
| May 5, 2026 | Craig-Hallum | Target | $70 | $85 | |
| May 5, 2026 | BTIG | Reiterate | Buy | $170 | $90 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | −$0.19 | $0.01 | +105.3% | $111.0M | $114.4M | +3.1% | +4.48% |
| May 4, 2026Q1 FY26 | −$0.06 | −$0.28 | −366.7% | $112.5M | $102.3M | −9.1% | −49.20% |
| Feb 23, 2026Q4 FY25 | $0.11 | $0.14 | +27.3% | $120.3M | $121.0M | +0.6% | −7.33% |
| Oct 28, 2025Q3 FY25 | $0.28 | $0.49 | +75.0% | $120.5M | $116.7M | −3.1% | −4.15% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $87.1M | $102.7M | $116.7M | $121.0M | $102.3M | $114.4M | |
| Gross profit | $58.5M | $70.9M | $84.5M | $78.9M | $68.2M | $78.2M | |
| Operating income | −$4.6M | $9.0M | −$3.3M | −$13.7M | −$26.2M | −$17.5M | |
| Net income | −$6.5M | $10.8M | −$7.6M | −$17.7M | −$63.3M | −$17.7M | |
| Diluted EPS | −$0.23 | $0.36 | −$0.27 | −$0.59 | −$2.16 | −$0.60 | |
| Gross margin | 67.1% | 69.0% | 72.4% | 65.2% | 66.7% | 68.4% | |
| Operating margin | -5.2% | 8.7% | -2.8% | -11.3% | -25.6% | -15.3% |
Fiscal years (4-quarter sums)FY21 $212.2M · FY22 $234.7M · FY23 $202.6M · FY24 $305.5M · FY25 $427.5M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $132.5M · Total debt $167.4M · Total assets $481.5M · Shareholders' equity $244.2M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 29.82M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Keith A. Meister · director, 10 percent owner: | 4.79M | 16.06% | Form 4 | Jun 23, 2026 |
| Corvex Management LP | 4.78M | 16.04% | 13F | Aug 14, 2026 |
| Casdin Capital, LLC | 3.71M | 12.43% | 13F | Aug 14, 2026 |
| OPKO Health, Inc. | 2.17M | 8.06% | 13D/A | Sep 18, 2024 |
| The Goldman Sachs Group, Inc. | 1.73M | 5.80% | 13G | Aug 11, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 16, 2026 | Katherine Stueland | director, officer: CHIEF EXECUTIVE OFFICER | −10,501 | $60.77 |
| Jun 16, 2026 | Kevin Feeley | officer: CHIEF FINANCIAL OFFICER | −3,729 | $60.77 |
| Jun 9, 2026 | Katherine Stueland | director, officer: CHIEF EXECUTIVE OFFICER | −3,639 | $53.77 |
| Jun 9, 2026 | Kevin Feeley | officer: CHIEF FINANCIAL OFFICER | −1,266 | $53.77 |
| Jun 4, 2026 | Casdin Capital, LLC | director, 10 percent owner: | +150,000 | $56.44 |
Peers
- Tempus AI
Ambry-backed genetic testing and AI precision-medicine rival
- Fulgent Genetics
Rare-disease NGS and ultra-rapid genome sequencing lab
- Labcorp
Scaled reference lab with Invitae genetics assets
- Quest Diagnostics
Blueprint-backed reference lab for rare-disease genetics
- Abbott
Public parent of Exact and PreventionGenetics diagnostics
- SOPHiA GENETICS
AI genomic-interpretation platform for rare-disorder workflows
- Natera
Prenatal and inherited-condition screening adjacency
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GeneDx | $87.15 | +0.93% | $2.57B | — | 132.3 | 5.7 | +11.4% |
| Tempus AI | $63.44 | −0.89% | $11.22B | — | — | 7.8 | +21.6% |
| Fulgent Genetics | $19.61 | −0.05% | $556.9M | — | — | 1.7 | +4.4% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| SOPHiA GENETICS | $8.10 | −0.31% | $682.9M | — | — | 7.9 | +27.2% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Median | 27.7 | 19.4 | 4.2 | +13.0% |